Drug Pricing: The Gross-to-Net Reality

Introduction

One of the most important lessons for anyone entering healthcare banking is that a drug's list price is not its revenue. The Wholesale Acquisition Cost (WAC), which is the price manufacturers set and the number reported in headlines about "drug price increases," is the starting point for a complex waterfall of discounts, rebates, chargebacks, and fees that ultimately determines what the manufacturer actually collects. For major branded drugs, these adjustments can reduce gross revenue by 30-70%, meaning a drug with a $100,000 annual list price might generate only $30,000-70,000 in net revenue per patient.

Understanding the gross-to-net (GTN) waterfall is essential for healthcare bankers because it directly affects revenue modeling, comparable company analysis, M&A valuation, and the interpretation of pharmaceutical financial statements.

The GTN waterfall traces the path from list price to net revenue. Each step represents a mandatory or negotiated discount that reduces the manufacturer's realization.

Wholesale Acquisition Cost (WAC)

The manufacturer's published list price for a drug, before any discounts, rebates, or price concessions. WAC is set unilaterally by the manufacturer (in the US) and serves as the starting point for all pricing discussions. It is roughly analogous to the "sticker price" of a car: a reference point that almost no one actually pays. WAC is sometimes called the "list price" or "catalog price."

The magnitude of each discount depends on the drug's therapeutic category, competitive position, channel mix, and negotiating dynamics.

PBM Rebates: The Largest Single Deduction

Pharmacy Benefit Managers (PBMs) negotiate rebates from pharmaceutical manufacturers in exchange for placing drugs on preferred formulary positions. The three largest PBMs (CVS Caremark, Express Scripts/Cigna, and OptumRx/UnitedHealth) control approximately 80% of the US prescription market, giving them significant negotiating leverage.

Rebate magnitude depends on therapeutic competition. In categories with multiple interchangeable branded drugs (e.g., statins, GLP-1 agonists, PPI inhibitors), PBMs can demand rebates of 40-60%+ by threatening to exclude the drug from formularies. In categories with limited competition (orphan drugs, first-in-class biologics), rebates are typically 10-20%.

340B: The Expanding Discount Program

The 340B Drug Pricing Program requires manufacturers to sell outpatient drugs at significant discounts (typically 25-60% below WAC) to covered entities, which include disproportionate share hospitals, federally qualified health centers, and certain other safety-net providers. The program has expanded dramatically, with 340B purchases now representing approximately 12-15% of US branded drug sales.

For pharmaceutical companies, 340B exposure is a growing GTN headwind because covered entities can purchase drugs at the discounted 340B price and receive full reimbursement from commercial insurers, pocketing the difference. This "340B spread" incentivizes covered entities to grow their 340B-eligible patient volumes, which increases the manufacturer's GTN deductions without a corresponding increase in patient access (the program's original intent).

Medicaid Best Price

The Medicaid Drug Rebate Program requires manufacturers to pay rebates to state Medicaid programs. The rebate is the greater of (1) 23.1% of Average Manufacturer Price (AMP) for branded drugs or (2) the difference between AMP and the "best price" offered to any commercial customer.

Best Price (Medicaid)

The lowest price available to any wholesaler, retailer, provider, HMO, or non-profit entity, excluding certain government prices (VA, 340B, nominal price sales). Best price is significant because it creates a floor on commercial discounting: if a manufacturer offers a very low price to any commercial customer, that price becomes the "best price" and increases the Medicaid rebate owed on every Medicaid unit sold. This constraint limits manufacturers' flexibility to offer deep commercial discounts and influences pricing strategy across all channels.

The gross-to-net waterfall has several direct implications for healthcare banking:

Acquisition due diligence. When valuing a pharma acquisition target, the buyer must understand the GTN waterfall for each major product. A drug with $2 billion in gross revenue and 50% GTN generates $1 billion in net revenue. If GTN is trending from 50% to 60% due to increasing PBM rebates and 340B exposure, the acquirer needs to model the revenue erosion even without competitive entry.

Comparable company analysis. GTN differences between companies can distort revenue-based comparisons. A specialty pharma company selling primarily through the 340B channel will have much higher GTN than one selling to the same patient population through commercial pharmacies. Normalizing for GTN differences improves the quality of peer comparisons.

This article concludes Section 2: Healthcare Industry Fundamentals. The regulatory frameworks (FDA pathways, patent protection, compliance laws) and payer dynamics (payer mix, reimbursement models, drug pricing) covered in this section provide the cross-cutting knowledge that applies to every sub-sector. The next section dives into the first major sub-sector: pharmaceuticals.